Publicaciones en las que colabora con ANA CONEJO GARCÍA (21)

2023

  1. N-aryltetrahydroisoquinoline derivatives as HA-CD44 interaction inhibitors: Design, synthesis, computational studies, and antitumor effect

    European Journal of Medicinal Chemistry, Vol. 258

  2. Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of the NPP1 enzyme

    Purinergic Signalling

2022

  1. Selective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles

    Pharmaceutics, Vol. 14, Núm. 4

2021

  1. Design, synthesis, HER2 inhibition and anticancer evaluation of new substituted 1,5-dihydro-4,1-benzoxazepines

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 36, Núm. 1, pp. 1553-1563

  2. Development of bozepinib-loaded nanocapsules for nose-to-brain delivery: Preclinical evaluation in glioblastoma

    Nanomedicine, Vol. 16, Núm. 23, pp. 2095-2115

  3. New insights into cytotoxic mechanisms of bozepinib against glioblastoma

    European Journal of Pharmaceutical Sciences, Vol. 162

2020

  1. Bozepinib: A Promising Selective Derivative Targeting Breast Cancer Stem Cells

    Translational Research in Cancer (IntechOpen)

2017

  1. 1-(Benzenesulfonyl)-1,5-dihydro-4,1-benzoxazepine as a new scaffold for the design of antitumor compounds

    Future Medicinal Chemistry, Vol. 9, Núm. 11, pp. 1129-1140

  2. Synthesis of 1,4-benzoxathiin-9H-purine derivatives as antiproliferative agents

    Targets in Heterocyclic Systems, Vol. 21, pp. 372-388

2014

  1. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound

    Oncotarget, Vol. 5, Núm. 11, pp. 3590-3606

2013

  1. Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence

    Drug Design, Development and Therapy, Vol. 7, pp. 1301-1313

2011

  1. New (RS)-benzoxazepin-purines with antitumour activity: The chiral switch from (RS)-2,6-dichloro-9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1- benzoxazepin-3-yl]-9H-purine

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 1, pp. 249-258

  2. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors

    Current Medicinal Chemistry, Vol. 18, Núm. 7, pp. 943-963

  3. Syntheses of 2,3-dihydro-1,4-benzodioxins and bioisosteres as structural motifs for biologically active compounds

    Current Organic Chemistry, Vol. 15, Núm. 6, pp. 869-887

2010

  1. Synthesis of purine derivatives as scaffolds for a diversity of biological activities

    Current Organic Chemistry, Vol. 14, Núm. 20, pp. 2463-2482

2009

  1. Homochiral drugs: A demanding tendency of the pharmaceutical industry

    Current Medicinal Chemistry, Vol. 16, Núm. 16, pp. 2064-2074

2008

  1. Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines

    Current Medicinal Chemistry, Vol. 15, Núm. 25, pp. 2614-2631

  2. From 5-fluorouracil acyclonucleosides to benzo-fused six- and seven-membered rings linked to pyrimidine and purine bases: The shift from differentiating anticancer agents to apoptotic inducers

    Expert Opinion on Drug Discovery, Vol. 3, Núm. 10, pp. 1223-1235

  3. Synthesis and anticancer activity of (R,S)-9-(2,3-dihydro-1,4-benzoxathiin- 3-ylmethyl)-9H-purines

    ChemMedChem, Vol. 3, Núm. 1, pp. 127-135

2005

  1. 1H and 13C spectral assignment of symmetrical bis[(4-aminosubstituted)quinolinium] derivatives

    Magnetic Resonance in Chemistry, Vol. 43, Núm. 12, pp. 1066-1071